Most importantly, in a phase I clinical trial of SIGLEC15-positive patients who were diagnosed with advanced/metastatic solid tumors refractory or resistant to currently available therapies with a tumor proportion score Tumor Proportion Score (TPS) PDL1 score <50% could benefit from NC318 (anti-SIGLEC15 antibody) (33). This evidence concerns the gene CD274 and neoplasm.